[go: up one dir, main page]

PE20091213A1 - Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico - Google Patents

Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico

Info

Publication number
PE20091213A1
PE20091213A1 PE2008001736A PE2008001736A PE20091213A1 PE 20091213 A1 PE20091213 A1 PE 20091213A1 PE 2008001736 A PE2008001736 A PE 2008001736A PE 2008001736 A PE2008001736 A PE 2008001736A PE 20091213 A1 PE20091213 A1 PE 20091213A1
Authority
PE
Peru
Prior art keywords
amino
metoxibipenil
etoxy
propanoic
pyrimidin
Prior art date
Application number
PE2008001736A
Other languages
English (en)
Inventor
Shinya Limura
Hui-Yin Li
Quiling Song
Wenxue Wu
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091213(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of PE20091213A1 publication Critical patent/PE20091213A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE AL COMPUESTO CRISTALINO ACIDO (S)-AMINO-3-(4-(2-AMINO-6-((R)-2,2,2-TRIFLUORO-1-(3´-METOXIBIFENIL-4-IL)ETOXI)PIRIMIDIN-4-IL)FENIL)PROPANOICO O UNA DE SUS SALES, CARACTERIZADO POR UN PATRON DE DIFRACCION DE POLVOS DE RAYOS X CON PICOS DE 3,5; 7,0; 8,6; 10,9; 13,5; 14,0; 15,1; 17,3 y/o 20,5 GRADOS 2 THETA. TAMBIEN SE REFIERE A UN METODO DE PREPARACION DE UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DE TRIPTOFANO HIDROXILASA (TPH), SIENDO DE UTILIDAD PARA EL TRATAMIENTO DE SINDROME CARCINOIDE, TRASTORNOS GASTROINTESTINALES O SINDROME DE INTESTINO IRRITABLE
PE2008001736A 2007-10-08 2008-10-07 Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico PE20091213A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97830307P 2007-10-08 2007-10-08

Publications (1)

Publication Number Publication Date
PE20091213A1 true PE20091213A1 (es) 2009-08-26

Family

ID=40344344

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001736A PE20091213A1 (es) 2007-10-08 2008-10-07 Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico

Country Status (20)

Country Link
US (1) US20090099206A1 (es)
EP (1) EP2231618A1 (es)
JP (1) JP2010540665A (es)
KR (1) KR20100066548A (es)
CN (1) CN101932563A (es)
AR (1) AR068837A1 (es)
AU (1) AU2008310979A1 (es)
BR (1) BRPI0818350A2 (es)
CA (1) CA2701904A1 (es)
CL (1) CL2008002980A1 (es)
CO (1) CO6270323A2 (es)
EA (1) EA201070455A1 (es)
EC (1) ECSP10010162A (es)
IL (1) IL204582A0 (es)
MX (1) MX2010003803A (es)
PE (1) PE20091213A1 (es)
TW (1) TW200932729A (es)
UY (1) UY31381A1 (es)
WO (1) WO2009048864A1 (es)
ZA (1) ZA201001870B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265495B (zh) 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
EA201070059A1 (ru) * 2007-06-26 2010-06-30 Лексикон Фармасьютикалз, Инк. Композиции, содержащие ингибиторы триптофангидроксилазы
TWI439457B (zh) 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
CA2719505A1 (en) 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
WO2011063181A1 (en) * 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
US20130303763A1 (en) * 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
US11203597B2 (en) * 2018-11-14 2021-12-21 Altavant Sciences Gmbh Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing
TW202210462A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 （ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基丙酸甲酯及其鹽的製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7382793B1 (en) * 2002-01-17 2008-06-03 Juniper Networks, Inc. Systems and methods for determining the bandwidth used by a queue
CN103265495B (zh) * 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EA201070059A1 (ru) * 2007-06-26 2010-06-30 Лексикон Фармасьютикалз, Инк. Композиции, содержащие ингибиторы триптофангидроксилазы
WO2009002964A1 (en) * 2007-06-26 2008-12-31 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
EP2170397A1 (en) * 2007-07-11 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods and compositions for treating pulmonary hypertension and related diseases and disorders
CA2694443A1 (en) * 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein

Also Published As

Publication number Publication date
ZA201001870B (en) 2011-06-29
JP2010540665A (ja) 2010-12-24
TW200932729A (en) 2009-08-01
KR20100066548A (ko) 2010-06-17
MX2010003803A (es) 2010-04-21
CA2701904A1 (en) 2009-04-16
UY31381A1 (es) 2009-04-30
BRPI0818350A2 (pt) 2017-10-10
AU2008310979A1 (en) 2009-04-16
CO6270323A2 (es) 2011-04-20
AR068837A1 (es) 2009-12-09
EP2231618A1 (en) 2010-09-29
CL2008002980A1 (es) 2009-03-20
IL204582A0 (en) 2010-11-30
ECSP10010162A (es) 2010-06-29
WO2009048864A1 (en) 2009-04-16
EA201070455A1 (ru) 2010-08-30
US20090099206A1 (en) 2009-04-16
CN101932563A (zh) 2010-12-29

Similar Documents

Publication Publication Date Title
PE20091213A1 (es) Formas solidas de acido (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-metoxibifenil-4-il)etoxi)pirimidin-4-il)fenil)propanoico
AR128483A2 (es) Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, sus composiciones y usos
ES2491140T3 (es) Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
PE20120171A1 (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh
AR084903A1 (es) Derivados de aminodihidrotiazina fusionada
BR112014015363A2 (pt) derivados de ácido alfa-amino borônico, inibidores de imunoproteassoma seletivos
GT200600420A (es) Sales novedosas de lisina de derivados de acido 4-((fenoxialquil)tio)-fenoxiacetico
AR066043A1 (es) Derivados de benzamida sustituida como inhibidores de la 11-beta-hidroxi esteroide deshidrogenasa tipo 1(11betahsd1)
AR114886A1 (es) Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CO6251286A2 (es) Sales amino del acido [4, 6-bis(dimetilamino)-2-(4-(4-trifluorometil)benzamido)bencil)pirimidin-5-il]acetico, composiciones farmaceuticas de las mismas y sus usos para el tratamiento de enfermedades mediadas por crth-2
PE20090742A1 (es) Formas solidas de (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)-pirimidin-4-il)fenil)propanoato de etilo y metodos para su uso
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
UY31738A (es) Inhibidores a base de hidroxamato de desacetilasas b
JP2015533810A5 (es)
EA201100994A1 (ru) Способ получения производных бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ лечения или профилактики ретровирусных инфекций с ее помощью
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CL2007003158A1 (es) Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
CY1112645T1 (el) Πολυμορφο β tου ν-(2-αμινοφαινυλο)-4-[ν-(πυριδινο-3-υλο)μεθοξυκαρβονυλ-αμινομεθυλο] βενζαμιδιου (μs-275)
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR083755A1 (es) Formas solidas del acido (s)-2-amino-3-(4-(-2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)pirimidin-4-il)fenil)propanoico
AR073842A1 (es) Derivados del acido 4- dimetilaminobutirico , proceso para su preparacion , composiciones farmacéuticas y uso de los mismos

Legal Events

Date Code Title Description
FC Refusal